There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cartesian Therapeutics (RNAC – Research Report) ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Learn more about whether Sarepta Therapeutics, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Sarepta Therapeutics hits 52-week lows despite strong earnings and growth. Read why investors should view SRPT as a high risk ...

Learn more about whether Kymera Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Charles Schwab Investment Management Inc. boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 2 ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sector ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.